After six years at the helm of the Neuroendocrine Tumor Research Foundation (NETRF) as its executive director, Ron Hollander has announced plans to step down.
Since joining in 2011, Ron Hollander helped transform NETRF from a small, grassroots organization to a major funder of NET research, recognized in the U.S. and abroad.
“With an expanded staff, solid operations, and a plan for continued growth and stability, I believe NETRF is well positioned for the future,” said Ron. “I’ve decided the time was right for me to take this step,”
Hollander secured significant philanthropic investment in NETRF to fuel its rapid growth. In 2015, a $15 million gift from the Margie and Robert E. Petersen Foundation accelerated NETRF’s funding of scientific research. NETRF set a new benchmark in 2017 by funding more than $4 million in NET research. That is more than double what was awarded the year Ron joined NETRF.
“The Board of Directors, scientific advisors, and staff of NETRF are thankful for Ron’s tireless commitment to advancing and expanding the Foundation,” said Joe Li, M.D., chair, NETRF Board of Directors. “As a result, NETRF is on course for continued progress and success.”
NETRF’s Senior Administrative Officer, Elyse Gellerman, MHS, will become Executive Director on November 13, 2017. “I am honored to be NETRF’S next Executive Director, said Elyse. “I am passionate about our mission to fund the best science and help patients live full lives.”
Elyse has made a significant impact on the organization since she joined NETRF in 2016. She has a rich background in nonprofit leadership, oncology, and healthcare operations. Elyse has a Bachelor’s Degree from Cornell University and a Master’s Degree in Healthcare Systems from the University of Denver.
“We are excited to welcome Elyse to this new role,” said Joe. “Ron, Elyse, NETRF staff, and the Board of Directors are working together to ensure a seamless and successful transition.”